Sort
3,198 grants matching “mrna vaccine”
Developing gene editing platforms for retinal degeneration.
$625,649Gaurav Sahay · Oregon State University · R01 · FY2024 · EY
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AVIAN MYCOPLASMOSIS IS ONE OF THE MAJOR THREATS TO POULTRY AND EGG PRODUCTION WORLDWIDE. THE PRIMARY ETIOLOGIC AGENT, MYCOPLASMA GALLISEPTICUM (MG), BELONGS TO A GENUS OF INSIDIOUS AND OBLIGATE BACTERIAL PATHOGENS AGAINST WHICH EFFECTIVE AND WELL-DEFINED VACCINES ARE LIMITED OR LACKING. THOUGH NON-CLASSICAL VIRULENCE FACTORS HAVE BEEN IDENTIFIED OR IMPLICATED IN MG AND OTHER MEMBERS OF THE GENUS MYCOPLASMA, TOOLS FOR GENETICALLY MODIFYING MYCOPLASMAS ARE ALSO LIMITED OR LACKING, MAKING DEVELOPMENT OF RATIONALLY DESIGNED ANTI-MYCOPLASMA VACCINES DIFFICULT. DESPITE THIS SHORTCOMING, RECENT ADVANCES IN ASSESSING IN-VIVO GENE EXPRESSION LEVELS IN MG DURING INFECTION OF THE NATURAL HOST HAS PROVIDED VALUABLE INSIGHTS INTO RESPONSES OF THE PATHOGEN AS IT STRIVES TO COLONIZE THE HOST. KNOWLEDGE OF SPECIFIC VIRULENCE DETERMINANT EXPRESSION IN THE INITIAL AND MOST CRITICAL PHASE OF INFECTION IS, FOR THE FIRST TIME, MAKING FEASIBLE THE CONSTRUCTION OF A RATIONALLY DESIGNED ANTI-MG VACCINE. HERE WE PROPOSE TO FURTHER DEVELOP AND REFINE OUR NEWLY CONSTRUCTED SUBUNIT MG VACCINE BASED ON OUR KNOWLEDGE OF ESSENTIAL VIRULENCE DETERMINANTS. WE BELIEVE THAT THIS VACCINE WILL HAVE SUPERIOR EFFICACY AND DESIGN FLEXIBILITY NOT AVAILABLE WITH THE COMMERCIALLY AVAILABLE BACTERIN (MG-BAC®). OUR VACCINE MAINTAINS A HIGH SAFETY PROFILE AND NO POSSIBILITY OF REVERSION TO VIRULENCE THAT CAN OCCUR WITH LIVE ATTENUATED VACCINES. OUR VACCINE IS AMENABLE TO RAPID MODIFICATION VIA THE INCORPORATION OF ADDITIONAL MG VIRULENCE DETERMINANTS IF NEEDED, OR PROTECTIVE ANTIGENS FROM OTHER SIGNIFICANT AVIAN PATHOGENS SUCH AS MYCOPLASMA SYNOVIAE. THIS PROGRESSIVE FORMAT IS ANALOGOUS TO THE APPROACH EMPLOYED IN THE DEVELOPMENT OF THE STREPTOCOCCUS PNEUMONIAE VACCINE, PREVNAR WHICH INCORPORATES PURIFIED CAPSULAR POLYSACCHARIDES FROM 13 SEROTYPES CONJUGATED TO DIPHTHERIA TOXOID PROVIDING A BROAD RANGE OF COVERAGE FROM PATHOGENIC SEROTYPES OF S. PNEUMONIAE. WE ALL HAVE ALL WITNESSED THE IMPRESSIVE SPEEDOF DEVELOPMENT OF NOVEL AND EFFICACIOUS COVID-19 VACCINES. WHILE MRNA-BASED VACCINES (E.G. COVID-19 VACCINES FROM MODERNA AND PFIZER) ARE NOT YET ECONOMICALLY OR LOGISTICALLY PRACTICAL FOR APPLICATIONS IN ANIMALS, OUR PROPOSED VACCINE IS. AND SIMILARLY, OUR VACCINE CAN BE MODIFIED VERY RAPIDLY WITH RELEVANT GENE SEQUENCE INFORMATION FROM OUTBREAKS OR FIELD STRAINS OF M. GALLISEPTICUM.
$625,000University Of Connecticut · · FY2022 · National Institute of Food and Agriculture
Regulation of germinal center responses by SARS-CoV-2 messenger RNA vaccines
$624,919Michela Locci · University Of Pennsylvania · R01 · FY2025 · AI
Molecular genetics and population studies of the KIR and HLA gene complexes
$624,706Mary N. Carrington · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Transcriptome Analysis with RNA-Reactive Probes
$623,371Eric T. Kool · Stanford University · R35 · FY2024 · GM
Transcriptome Analysis with RNA-Reactive Probes
$623,371Eric T. Kool · Stanford University · R35 · FY2025 · GM
Transcriptome Analysis with RNA-Reactive Probes
$623,371Eric T. Kool · Stanford University · R35 · FY2023 · GM
Profiling the Leishmania-macrophage Host-pathogen Infectome
$623,093Najib M. El-Sayed · Univ Of Maryland, College Park · R01 · FY2014 · AI
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
$622,145Annette H Sohn · Foundation For Aids Research · R01 · FY2014 · HD
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responses
$622,103Norbert Pardi · University Of Pennsylvania · R01 · FY2020 · AI
Endothelial cell-assisted extracellular vesicle bioengineering for cytoplasmic delivery of therapeutic molecules
$622,000Clair Crewe · Washington University · R21 · FY2024 · EB
SARS-CoV-2 Vaccine Responses in children with genetic or acquired B cell deficiencies
$621,860Wen-Yuan E Hsieh · University Of Colorado Denver · R01 · FY2022 · AI
Optimization and Pre-Clinical Evaluation of New Strategies for HIV-1 Prevention and Treatment
$621,528Paolo Lusso · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Mechanisms of action, optimization and application of Bregs
$619,816James F Markmann · University Of Pennsylvania · R01 · FY2024 · AI
Designing HIV-1 envelope immunogens to maximize neutralization breadth through use of multiple founder envelope antigens
$619,289Sandhya Vasan · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2023 · AI
Developing gene editing platforms for retinal degeneration.
$617,949Gaurav Sahay · Oregon State University · R01 · FY2025 · EY
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020
$617,119Elias Sayour · University Of Florida · R01 · FY2024 · FD
Identification of human tumor-associated antigens
$617,092Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Dengue virus mRNA lipid nanoparticle vaccine
$616,537Justin Richner · University Of Illinois At Chicago · R01 · FY2024 · AI
Interactions of Retroviral Proteins with Nucleic Acids
$616,301Alan Rein · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Genetics of Coxiella burnetii
$615,587Robert A Heinzen · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Vanderbilt Vaccine and Treatment Evaluation Unit
$614,901Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2021 · AI
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINS
$614,163Margie Clapper · Research Inst Of Fox Chase Can Ctr · N01 · FY2022 · CA
Innovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumors
$614,124Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2025 · CA
Dengue virus mRNA lipid nanoparticle vaccine
$614,090Justin Richner · University Of Illinois At Chicago · R01 · FY2023 · AI